Sionna Therapeutics’ PreciSION CF clinical trial will not advance to the next phase

The PreciSION CF study did not meet its primary efficacy endpoint.

The Phase 2a study did not show a significant reduction in sweat chloride in cystic fibrosis patients compared to standard therapy.

The Phase 2a results are available online (https://investors.sionnatx.com/news-releases/news-release-details/sionna-therapeutics-reports-topline-data-two-development).